Ovid Therapeutics Inc.
OVIDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Ovid Therapeutics Inc. focuses on Biotechnology services and products. Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the. At a $492.7M market cap, Ovid Therapeutics Inc. ranks as a small-cap company within healthcare. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Market Cap
$492.7M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-5.84
EPS (TTM)
$-0.21
EPS (Fwd)
$-0.45
ROE
-18.8%
ROA
-19.4%
Cash
$155.5M
Total Debt
$13.1M
Free CF
-$20.2M
52W Change
870.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $155.5M in cash comfortably exceeding the $13.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$20.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -18.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.5M (2022) to $7.3M (2025), reflecting a 383% increase over the period.
With cash comfortably exceeding debt, OVID has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ovid Therapeutics Inc.'s trajectory.